Best Health Care Stocks for 2025
Re: Best Health Care Stocks for 2025
Vertex Pharmaceuticals Inc. (VRTX)
Vertex Pharmaceuticals is a biopharmaceutical company that specializes in developing therapies to treat cystic fibrosis. Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics AG (CRSP) gene-editing therapy exagamglogene autotemcel (Casgevy), which was approved by the Food and Drug Administration for treating sickle cell disease in December 2023 and for treating transfusion-dependent beta thalassemia six weeks later. Hardy says the recent FDA approval of non-opioid painkiller Journavx for adults with moderate to severe acute pain will be another Vertex catalyst. CFRA has a "buy" rating and $561 price target for VRTX stock, which closed at $484.01 on April 3.
Vertex Pharmaceuticals is a biopharmaceutical company that specializes in developing therapies to treat cystic fibrosis. Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics AG (CRSP) gene-editing therapy exagamglogene autotemcel (Casgevy), which was approved by the Food and Drug Administration for treating sickle cell disease in December 2023 and for treating transfusion-dependent beta thalassemia six weeks later. Hardy says the recent FDA approval of non-opioid painkiller Journavx for adults with moderate to severe acute pain will be another Vertex catalyst. CFRA has a "buy" rating and $561 price target for VRTX stock, which closed at $484.01 on April 3.